Drug reference

sargramostim

Recombinant granulocyte-macrophage colony-stimulating factor

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

1 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactions

CladribineSevereDatabaseDDInter

Mechanism

Not yet extracted

Indications

stimulate myelopoiesisacceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantationpromotion of neutrophil recovery following chemotherapymobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patientsacute exposure to myelosuppressive doses of radiationinduction of neutrophil production following chemotherapyautologous marrow transplantation (shortens duration of neutropenia)allogeneic transplantation (may improve survival in early graft failure)mobilize CD34-positive progenitor cells for peripheral blood stem cell collectionshorten neutropenia in patients receiving intensive cancer chemotherapycyclic neutropeniamyelodysplasiaaplastic anemiaAIDS-associated neutropenia

Dosing

Adult: 125 to 500 μg/m2 per day by subcutaneous injection or slow intravenous infusion. Administered daily during the period of maximum neutropenia until a sustained rise in the granulocyte count is observed.

Pharmacokinetics

Half-life

2 to 3 h (subcutaneous)

Side effects

Common

infusion-related reactions (respiratory distress, hypoxia, flushing, hypotension, syncope, and/or tachycardia)bone painmalaiseflu-like symptomsfeverdiarrheadyspnearash

Serious

acute reaction (flushing, hypotension, nausea, vomiting, dyspnea, fall in arterial oxygen saturation, granulocyte sequestration in pulmonary circulation)
capillary leak syndrome
peripheral edema
pleural effusions
pericardial effusions
transient supraventricular arrhythmia
elevation of serum creatinine
elevation of bilirubin
elevation of hepatic enzymes